JP2006503807A5 - - Google Patents

Download PDF

Info

Publication number
JP2006503807A5
JP2006503807A5 JP2004511287A JP2004511287A JP2006503807A5 JP 2006503807 A5 JP2006503807 A5 JP 2006503807A5 JP 2004511287 A JP2004511287 A JP 2004511287A JP 2004511287 A JP2004511287 A JP 2004511287A JP 2006503807 A5 JP2006503807 A5 JP 2006503807A5
Authority
JP
Japan
Prior art keywords
disorder
pharmaceutical preparation
compound according
drug
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004511287A
Other languages
English (en)
Japanese (ja)
Other versions
JP4342437B2 (ja
JP2006503807A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/015405 external-priority patent/WO2003104217A2/en
Publication of JP2006503807A publication Critical patent/JP2006503807A/ja
Publication of JP2006503807A5 publication Critical patent/JP2006503807A5/ja
Application granted granted Critical
Publication of JP4342437B2 publication Critical patent/JP4342437B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2004511287A 2002-06-11 2003-06-06 興奮性アミノ酸のプロドラッグ Expired - Lifetime JP4342437B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP02380121 2002-06-11
EP02380120 2002-06-11
US41593602P 2002-10-03 2002-10-03
US41593702P 2002-10-03 2002-10-03
PCT/US2003/015405 WO2003104217A2 (en) 2002-06-01 2003-06-06 Prodrugs of excitatory amino acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008031490A Division JP2008201779A (ja) 2002-06-11 2008-02-13 興奮性アミノ酸のプロドラッグ

Publications (3)

Publication Number Publication Date
JP2006503807A JP2006503807A (ja) 2006-02-02
JP2006503807A5 true JP2006503807A5 (cg-RX-API-DMAC7.html) 2008-04-03
JP4342437B2 JP4342437B2 (ja) 2009-10-14

Family

ID=29740902

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004511287A Expired - Lifetime JP4342437B2 (ja) 2002-06-11 2003-06-06 興奮性アミノ酸のプロドラッグ
JP2008031490A Pending JP2008201779A (ja) 2002-06-11 2008-02-13 興奮性アミノ酸のプロドラッグ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008031490A Pending JP2008201779A (ja) 2002-06-11 2008-02-13 興奮性アミノ酸のプロドラッグ

Country Status (29)

Country Link
US (5) US7371872B2 (cg-RX-API-DMAC7.html)
EP (2) EP1897550A3 (cg-RX-API-DMAC7.html)
JP (2) JP4342437B2 (cg-RX-API-DMAC7.html)
KR (1) KR20080058509A (cg-RX-API-DMAC7.html)
AR (1) AR040257A1 (cg-RX-API-DMAC7.html)
AT (1) ATE421526T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003232146B2 (cg-RX-API-DMAC7.html)
BR (1) BR0311558A (cg-RX-API-DMAC7.html)
CA (1) CA2488167C (cg-RX-API-DMAC7.html)
CO (1) CO5631438A2 (cg-RX-API-DMAC7.html)
CR (2) CR7616A (cg-RX-API-DMAC7.html)
CY (1) CY1108976T1 (cg-RX-API-DMAC7.html)
DE (1) DE60325968D1 (cg-RX-API-DMAC7.html)
DK (1) DK1517915T3 (cg-RX-API-DMAC7.html)
EA (2) EA014979B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP085481A (cg-RX-API-DMAC7.html)
ES (1) ES2319116T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20041179B1 (cg-RX-API-DMAC7.html)
IL (2) IL165100A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04012518A (cg-RX-API-DMAC7.html)
MY (1) MY146238A (cg-RX-API-DMAC7.html)
NO (2) NO331780B1 (cg-RX-API-DMAC7.html)
NZ (3) NZ556437A (cg-RX-API-DMAC7.html)
PE (1) PE20040555A1 (cg-RX-API-DMAC7.html)
PL (1) PL221489B1 (cg-RX-API-DMAC7.html)
PT (1) PT1517915E (cg-RX-API-DMAC7.html)
SI (1) SI1517915T1 (cg-RX-API-DMAC7.html)
WO (1) WO2003104217A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200409553B (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20041179B1 (hr) * 2002-06-11 2012-11-30 Eli Lilly And Company Prekursorski oblici lijekova za aminokiseline s pobuđivačkom aktivnosti
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EA017648B1 (ru) 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としての3−アザビシクロ[3.1.0]ヘキシル誘導体
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
WO2010111080A2 (en) 2009-03-27 2010-09-30 Eli Lilly And Company Optimized treatment of schizophrenia
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102549138B (zh) * 2009-06-29 2015-04-01 伊诺莱克斯投资公司 不含石化衍生中性氨基酸酯的阳离子型乳化剂及其组合物和方法
JO2978B1 (en) * 2009-12-21 2016-03-15 ايلي ليلي اند كومباني MGLU2 aids
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
CN103209954B (zh) * 2010-11-18 2015-09-02 伊莱利利公司 作为mGluR2/3拮抗剂的4-取代的-3-苄氧基-双环[3.1.0]己烷化合物
AR083845A1 (es) 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
KR101598679B1 (ko) * 2011-06-17 2016-02-29 일라이 릴리 앤드 캄파니 mGlu2 수용체 효능제로서의 비시클로(3.1.0)헥산-2,6-디카르복실산 유도체
AR089718A1 (es) * 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
EP2857385B1 (en) 2012-06-01 2017-08-02 Taisho Pharmaceutical Co., Ltd. Prodrug of fluorine-containing amino acid
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) * 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PL3096790T3 (pl) * 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
ME03518B (me) * 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
CN108752212B (zh) * 2015-03-06 2024-03-12 北京大学 9-脱羧迷迭香酸类似物及其合成方法和应用
KR102056257B1 (ko) 2015-07-09 2019-12-16 미메토젠 파르마슈티칼스 인크. 베타-턴 펩티도미메틱 사이클릭 염의 용액상 합성 및 결정화

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US200488A (en) 1878-02-19 Improvement in temporary binders
US1459765A (en) * 1922-03-18 1923-06-26 Wordsworth M Elliott Interchangeable sign letters
WO1993006127A1 (en) * 1991-09-17 1993-04-01 Warner-Lambert Company Novel amino acid prodrug renin inhibitors
US5849525A (en) 1994-03-09 1998-12-15 Brigham And Women's Hospital, Inc. Compositions corresponding to a proton-coupled peptide transporter and methods of making and using same
DE69529209T2 (de) * 1995-03-14 2003-11-13 Brown & Sharpe Tesa S.A., Renens Element mit einem geregelten Diodenlaser, und elektrooptische Vorrichtung unter Verwendung eines derartigen Elements
JP2000500748A (ja) * 1995-11-16 2000-01-25 イーライ・リリー・アンド・カンパニー 興奮性アミノ酸誘導体
US5688826A (en) * 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
US5952294A (en) 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
ZA983930B (en) * 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
CN1182105C (zh) * 1998-01-28 2004-12-29 大正制药株式会社 含氟氨基酸衍生物
DE69918136T2 (de) * 1998-08-31 2005-07-07 Taisho Pharmaceutical Co., Ltd. 6-Fluorobicyclo[3.1.0]Hexan-Derivate
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6313498B1 (en) * 1999-05-27 2001-11-06 Actrans System Inc. Flash memory cell with thin floating gate with rounded side wall, and fabrication process
CN1216038C (zh) * 2000-06-28 2005-08-24 大正制药株式会社 新型二羧酸衍生物
WO2002055485A1 (en) * 2001-01-11 2002-07-18 Eli Lilly And Company Prodrugs of excitatory amino acids
US7256217B2 (en) * 2001-01-11 2007-08-14 Eli Lilly And Company Prodrugs of excitatory amino acids
EP1395257A1 (en) * 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
PL208123B1 (pl) * 2001-12-27 2011-03-31 Taisho Pharmaceutical Co Ltd Pochodna kwasu 2-amino-3-alkoksy-6-fluorobicyklo [3.1.0] heksano-2, 6-dikarboksylowego, zawierająca ją kompozycja farmaceutyczna i lek, oraz jej zastosowanie
US20050192273A1 (en) * 2002-04-03 2005-09-01 Johnson Bryan G. Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
WO2003084610A1 (en) * 2002-04-03 2003-10-16 Eli Lilly And Company Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
HRP20041179B1 (hr) * 2002-06-11 2012-11-30 Eli Lilly And Company Prekursorski oblici lijekova za aminokiseline s pobuđivačkom aktivnosti

Similar Documents

Publication Publication Date Title
TW513416B (en) Pyrazine compounds and pharmaceutical composition thereof useful as sodium channel blocker
JP2024050607A (ja) 結晶性の置換シクロヘキシルピラゾロ[1,5-a]ピリミジニルカルボキサミド化合物およびその治療的使用
JP7279758B2 (ja) テトラヒドロナフタレン誘導体
MXPA05000435A (es) Derivados de azabiciclo como antagonistas de receptor muscarinico.
JP2009137943A (ja) アゴメラチンの新規な結晶形vi、その製造法、およびそれを含有する薬学的組成物
JP2004527467A5 (cg-RX-API-DMAC7.html)
JPH06508816A (ja) (s)(+)−2−エトキシ−4−[n−[1−(2−ピペリジノ−フェニル)−3−メチル−1−ブチル〕アミノカルボニルメチル〕−安息香酸、この化合物を含む医薬組成物及びその調製方法
JPWO2002010101A1 (ja) アミド化合物を配位子とする遷移金属錯体を用いたアルコールの製造方法
KR101369126B1 (ko) 탄소환 glyt1 수용체 길항제
CA2540768A1 (en) Pyrazolo and imidazo-pyrimidine derivatives
CA2554536A1 (en) Crystalline forms of gaboxadol monohydrate or anhydrate
WO2017190609A1 (zh) 一种高效合成西他沙星中间体(7s)-5-氮杂螺[2.4]庚烷-7-基氨基甲酸叔丁酯的制备方法
CA2873658C (en) Process for making amino acid compounds
JP7354960B2 (ja) S1p5介在性疾患の予防および/または治療剤
DE69621877T2 (de) 4-Indolylpiperazinyl-Derivate
WO2010000196A1 (zh) 一种奥卡西平的化学合成方法
JP5250205B2 (ja) トルテロジン、その組成物及び使用、及びその製造方法
JPWO2010055911A1 (ja) ビフェニルアセトアミド誘導体
JPH02169558A (ja) 心臓および循環器疾患の治療薬および新規ニトロキシアルキルアミン誘導体
CN1083843C (zh) 2-(氨基甲基)-3,4,7,9-四氢-2H-吡喃并[2,3-e]吲哚-8-酮及其衍生物和药物组合物
JP2004524292A5 (cg-RX-API-DMAC7.html)
EP0489548B1 (en) A process for the preparation of 2(R)-methyl-4,4,4-trifluorobutylamine, intermediates, and a process for the preparation of a derivative thereof
CA2433667A1 (en) Prodrugs of excitatory amino acids
JP2007538061A (ja) カルベジロールの製造方法
JP2003514889A (ja) O−デスメチルベンラファキシンのエーテル